Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2021
Drug name
KINERET® (anakinra)
Company
Swedish Orphan Biovitrum
Decision date
05/11/2021
Therapeutic area
Genetic conditions
Therapeutic sub area
Genetic conditions: general and other
Decision
Not recommended
Indication
Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, anakinra (Kineret®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result it cannot be recommended for use within NHS Scotland.